Posted by Michael Wonder on 18 Oct 2024
Alhemo recommended for European approval as first once daily subcutaneous prophylactic treatment for people living with haemophilia A or B with inhibitors
18 October 2024 - Novo Nordisk today announced that the EMA's CHMP has adopted a positive opinion, recommending approval of Alhemo (concizumab) as the first once daily subcutaneous prophylactic treatment for people aged 12 years or older living with haemophilia A or B with inhibitors.
The CHMP positive opinion is based on data from the phase 3 explorer7 study, which was designed to evaluate the efficacy and safety profile of Alhemo for people living with haemophilia A or B with inhibitors.
